IP Library › Granted Patent US 9,061,073
Granted Patent B2
US 9,061,073 · App. 13/563,372 · Granted Jun 23, 2015

Antibody-light fusion products for cancer therapeutics

Inventor: Yang-Xin Fu (Chicago, IL)
Assignee: The University of Chicago
A61K47/48569A61K47/48423A61K2039/507C07K14/5255C07K2319/33C12N2799/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,061,073
App. No.
13/563,372
Granted
Jun 23, 2015
Kind
B2
Abstract

Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.

Claims (3)

1. A composition comprising a fragment of a protease resistant LIGHT protein in combination with an agent that specifically recognizes a tumor cell, wherein the LIGHT protein and agent are not physically linked, and wherein the fragment is capable of being stably present on a tumor cell surface and is sufficient to stimulate cytotoxic T-lymphocytes against tumor cells.

2. The composition of claim 1 , wherein the agent is an antibody against a tumor antigen.

3. The composition of claim 1 , wherein the agent is a ligand that binds a tumor surface receptor.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 1, 2020
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053656/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2012
From: FU, YANG-XIN
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 028759/0850 →
Continuity (3)
Division 12599946
Provisional Application 60917852 · May 14, 2007
Related Publication 20120328558A1 · Dec 27, 2012